Eli Lilly, Ascidian Sign $1.9 Billion Kidney-Disease Treatment Deal
RSS SUMMARY · AGGREGATED FROM TWSJ
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Eli Lilly signed a collaboration and licensing agreement worth up to $1.9 billion with Ascidian Therapeutics to research and develop kidney-disease treatments.
Continue Reading
The full story continues on The Wall Street Journal.
Story Sentry shows a short summary aggregated via RSS. The complete article — original photography, charts, and reporting — lives with the publisher.
The Source
TWSJ
Business
Opinion | The Market Has Spoken: E15 Is a Net Positive
TWSJ·53m ago·3 min read
Business
U.S. Services-Sector Activity Continued to Expand in May
TWSJ·1h ago·3 min read
World News
Ukraine Strikes St. Petersburg Ahead of Putin’s Economic Forum
TWSJ·1h ago·3 min read
World News
Canada Orders Broadcast Regulator to Review Contentious Online Streaming Decision
TWSJ·1h ago·3 min read
Related
On this beat
Tech
Microsoft and OpenAI broke up — now they’re ready to fight
THE VERGE·1h ago·3 min read
Tech
Best peripherals of Computex 2026: top new keyboards and mice you need to know about
TECHRADAR·1h ago·3 min read
Tech
Weedhack malware campaign infects 116,000 mod-hungry Minecraft players systems through SEO poisoning and YouTube
TECHRADAR·1h ago·3 min read
Tech
Why Legacy Modernization Fails
FORBES·1h ago·3 min read